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1. Introduction 
Celiac disease is a systemic disease, which is associated with a number of hematologic 
manifestations. Individuals can present with hematological abnormalities even prior to  the 
diagnosis of celiac disease. Anemia secondary to iron, folic acid and vitamin B12 
malabsorption is a common complication of celiac disease. Patients can also present with 
thrombocytosis, thrombocytopenia, leukopenia, venous thromboembolism, hyposplenism 
and IgA deficiency. Celiac disease also predisposes to lymphoma development. The highest 
risk is for enteropathy associated T-cell lymphoma (EATL), an aggressive lymphoma with 
poor prognosis, however an increased risk for B-cell lymphomas and extraintestinal 
lymphomas has been described. Strict adherence to a gluten-free diet is known to decrease 
the risk of lymphomas.  
2. Anemia 
Anemia is a frequent finding in patients with celiac disease (CD) and may be the 
presenting feature. It may also be the only abnormality identified. Anemia was particularly 
common in patients with untreated CD in the past, but it is still frequently encountered in 
undiagnosed adults.1,2,3,4 The etiology of anemia in celiac disease is multifactorial. The 
anemia is usually hypoproliferative, reflecting impaired absorption of essential nutrients 
like iron and various vitamins. In prior studies, the overall prevalence of anemia at the 
time of diagnosis of celiac disease has been estimated between 12 and 69%. 5,6,7 Anemias 
caused by hemolysis are very rarely reported in celiac disease patients. Ivanovski et al. 
reported an 11-year old girl with untreated celiac disease who had hemolytic anemia and 
suggested that CD should be serologically screened in patient‘s with Coombs negative 
"immune" hemolytic anemia. As in this case the anemia improved after initiating a gluten 
free diet. 8 
2.1 Mechanisms of anemia in celiac disease  
A number of causative factors deserve consideration for explaining the mechanism of 
anemia in celiac disease.  
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2.1.1 Abnormal iron absorption 
The most obvious cause of anemia in celiac disease is impaired absorption of iron and other 
nutrients including folate and cobalamin. Iron is absorbed in the proximal small intestine 
and the absorption is dependent upon several factors, including an intact mucosal surface 
and intestinal acidity.9 Villous atrophy of the intestinal mucosa is an important cause of 
abnormal iron absorption, which is reflected as laboratory evidence of iron deficiency 
anemia (IDA) in most anemic patients with celiac diasease. Abnormal iron absorption is also 
supported by the failure to increase serum iron levels following oral iron loading and 
refractoriness to oral iron treatment. 1,2,3 
2.1.2 Increased blood loss 
Occult gastrointestinal blood loss was detected in about half the patients with celiac disease 
in one study, and this finding appeared to correlate with the severity of villous atrophy. 16 
An important limitation of that study was the use of an indirect (guaiac) test for detecting 
bleeding. In a subsequent study employing 51 Cr radiolabeled red blood cells, a daily blood 
loss exceeding 1.5 mL was detected in only one of 18 subjects studied. Others have also found 
that the rate of positive occult blood tests in celiac disease is low and does not exceed that in 
the general population. Thus, the evidence supporting increased fecal blood loss in celiac 
disease remains controversial, and although abnormal intestinal bleeding may occur in some 
celiac patients, it does not appear to play a significant role in the causation of anemia. 1,16 
2.1.3 Abnormal vitamin absorption 
The anemia seen in celiac disease can also result from malabsorption of various 
micronutrients necessary for normal hematopoiesis. Sideropenia, vitamine B12 and folat 
acide deficiency has been described in patients with celiac disease. 1, 39, 52 Copper 
deficiency has been described in adults and children with CD and may result in anemia and 
thrombocytopenia. 17, 18 Deficiencies in vitamin B6, pantothenic acid, and riboflavin have 
also been suggested as etiologic factors in patients with CD but recent data are lacking.1 
2.1.4 Inflammation 
Pro-inflammatory cytokines play an essential role in the inflammatory and cytotoxic 
mechanisms involved in the pathogenesis of celiac disease. Such cytokines, in particular 
interferon- γ (IFN-γ), and IL6, are powerful mediators of hypoferremia in inflammation 
inducing the synthesis of the iron regulatory hormone hepcidin.15, 19, 20, 22 Increased 
hepcidin synthesis in turn is responsible for increased ferroportin degradation and the 
inhibition of iron release from macrophages and enterocytes leading to the well known 
abnormalities in iron homeostasis associated with anemia of chronic disease (ACD).  19 
2.2 Iron-deficiency anemia 
Iron-deficiency anemia (IDA) is the most commonly encountered anemia in humans and is 
usually due to either increased iron loss or impaired absorption of iron.23 Iron-deficiency 
anemia is frequently seen in patients with celiac disease and can be found even in the 
absence of diarrhea or steatorrhea. IDA has been reported in up to 46% of cases of 
subclinical CD, with a higher prevalence in adults than children.3, 9 Iron deficiency has also 
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been reported in patients with dermatitis herpetiformis. 10 IDA usually manifests as 
microcytic, hypochromic anemia and patients characteristically have low serum iron levels, 
elevated total iron-binding capacity, and low ferritin levels. 9, 11 Measurements of soluble 
transferrin receptors (sTfRs) can also be valuable in the evaluation of IDA, and the ratio of 
sTfR to ferritin may indicate CD in children with refractory IDA.12 Iron deficiency that is 
refractory to therapy can be the sole manifestation of CD, especially in pediatric patients and 
the prevalence of CD in patients with refractory IDA may be as high as 20%13, 14, 15. Fayed 
et al. reported that refractory IDA may be due to clinically unapparent CD in children. They 
recommended treatment with a gluten-free diet rich in iron and suggested that early 
detection and treatment of IDA with prophylactic iron and folic acid supplementation 
would go a long way in preserving good mental and psychological functions. 35 Patients 
with anemia had low levels of erythropoietin for the degree of anemia and increased serum 
interferon-gamma.This study supported the hypothesis that anemia in celiac disease is 
multifactorial in etiology and suppression of intestinal inflammatory changes as a result of a 
gluten-free diet improves anemia by correcting iron and vitamin malabsorption as well as 
mechanisms contributing to anemia of chronic disease. 19, 20 
The prevalence of celiac disease in patients presenting with iron-deficiency anemia ranges 
from 0 to 8.7%. 23, 24, 25, 26, 27, 28 In a study conducted in Italy, anemic patients were 
screened for celiac disease using antigliadin and antiendomysial antibodies. 14 Jejunal 
biopsies were obtained from patients with positive serology. The prevalence of celiac 
disease was 5% in all patients with anemia and 8.5% in those with iron-deficiency anemia. 
23 In a study conducted in the United Kingdom, 115 patients with iron deficiency anemia 
were assessed with esophagogastroduodenoscopy, flexible sigmoidoscopy, and barium 
enema; 2.6% of these patients had celiac disease. However, fewer than half of the patients 
underwent a small bowel biopsy, and hence the true prevalence of celiac disease might have 
been underestimated. Of interest, however, the three patients with celiac disease had normal 
appearing mucosa on small bowel endoscopy. 25 In two studies, biopsies were performed 
on the patients with positive serology, and the prevalence of biopsy-proven CD was 2.3% to 
4.7%. 25, 27 Iron deficiency in celiac disease primarily results from impaired absorption of 
iron but there may also be occult blood loss in the gastrointestinal (GI) tract. 31, 32 Occult 
gastrointestinal bleeding was detected in 25% to 54% of patients with CD, depending on the 
degree of villous atrophy, in 1 study. 16 Occult GI blood loss was seen in 26.7% of children 
with CD that appeared to respond to treatment with a gluten-free diet (GFD), according to 
another study. 33 More-recent studies have, however, suggested that occult GI bleeding in 
patients with CD may be much less common. 34, 35  Biopsy-proven CD was reported in 
2.6% to 5% of patients. 23, 28 Three other studies included patients with anemia other than 
IDA but the vast majority in all 3 studies suffered from IDA. 25, 29, 30 Serologic evidence of 
CD was observed in 2.3% to 10.9% of these anemic patients. In 2 of the studies, biopsies 
were performed on the patients with positive serology, and the prevalence of biopsy-proven 
CD was 2.3% to 4.7%. 25, 30 One of the studies suggested that history of chronic diarrhea 
predicted CD as the cause for the anemia. 36 Clinicians should consider CD as a possible 
cause of anemia in all subjects with unexplained IDA, including menstruating women. 
Endoscopic markers of CD in patients with IDA have been shown to lack sensitivity for 
diagnosis and have limited utility in selecting patients for a small-bowel biopsy. 38 biopsies 
should be performed even if the duodenal mucosa appears normal to the endoscopist. One 
recent study has shown that many patients undergoing an endoscopy for anemia do in fact 
not have a small-bowel biopsy performed.39 In conclusion, IDA is common in CD, and CD 
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is frequently found in patients presenting with IDA. The treatment of IDA associated with 
CD is primarily a GFD and iron supplementation until the iron stores have been restored. 
2.2.1 Folate deficiency 
Folic acid is an element essential for amino acid and nucleic acid metabolism. Adequate folic 
acid is required for normal hematopoiesis and development of the nervous system. 40 Folic acid 
is primarily absorbed in the jejunum, and malabsorption is frequent in diseases of the small 
intestine. 40, 41 Deficiency of folic acid usually presents as macrocytic or megaloblastic anemia, 
but abnormalities of other cell lineages are common. Concomitant iron deficiency as seen in CD 
can result in atypical findings on the blood smear, and patients with deficiencies of folate and 
vitamin B12 may not present with the characteristic macrocytosis. Examination of the blood 
smear may reveal a dimorphic picture reflecting the effects of both deficiencies. Severe folic-acid 
deficiency can result in a decrease in both leukocytes and platelets and even manifest as severe 
pancytopenia. The diagnosis is usually made by measuring serum folate and red-cell folate 
levels. Serum folate is highly dependent on folate intake and is frequently increased in patients 
with deficiency of vitamin B12. Red-cell folate is not specific for folate deficiency, as it can be 
decreased in patients with vitamin B12 deficiency, but red-cell folate is less subject to transient 
changes secondary to variations in folate intake. 41 Elevated serum homocysteine levels can be 
helpful in diagnosing folate deficiency but the sensitivity of serum homocysteine is somewhat 
less for vitamin B12 deficiency. 43, 44 Previous studies have shown that many untreated 
patients with CD are folate deficient. 45Two small studies found that folate deficiency is a 
common finding in children, but it does not usually result in anemia. 46, 47 More-recent studies 
have confirmed that folic-acid deficiency continues to be a frequent finding in subjects with 
newly diagnosed CD and can be observed even in adolescents and young adults with CD 
detected by screening. 30, 48, 49 Folate deficiency has also been reported in association with 
dermatitis herpetiformis. 50, 51 Homocysteine levels are commonly elevated in CD patients at 
the time of diagnosis and may serve as a diagnostic clue. 52  
2.2.2 Vitamin B12 deficiency 
Vitamin B12 is an essential cofactor and a coenzyme in multiple biochemical pathways, 
including the pathways of DNA and methionine synthesis. While the main site of vitamin B12 
absorption is the distal ileum (where it is absorbed bound to intrinsic factor), a small 
proportion is also absorbed passively along the entire small bowel. 53 Although celiac disease 
has been considered a disorder of the proximal small bowel, associated vitamin B12 deficiency 
has been reported. Deficiency of vitamin B12 is common in CD and frequently results in 
anemia. Malabsorption of vitamin B12 resulting in anemia has also been described in patients 
with dermatitis herpetiformis (DH). 54 Dickey et al. in their study reported, that of 159 
patients, 13 had low serum B12 at diagnosis. A further six had been receiving B12 replacement 
therapy for 3-37 years before diagnosis, giving an overall prevalence of 12% (19 patients). Only 
2 of 19 patients had gastric corpus atrophy, one with intrinsic factor antibodies and the other 
with hypergastrinaemia. There was no relationship between low B12 levels and clinical 
characteristics. 55 The cause of vitamin B12 deficiency in CD is unclear.  It  may include 
decreased gastric acid, bacterial overgrowth, autoimmune gastritis, decreased efficiency of 
mixing with transfer factors in the intestine, or perhaps dysfunction (inflammation) of the 
distal small intestine. 56, 57 Recent studies suggested that 8% to 41% of previously untreated 
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subjects with CD were deficient in vitamin B12. 58, 59 Bode et al. In their study reported an 
11% incidence of vitamin B12 deficiency in 50 consecutively diagnosed patients with CD. 60 
Measurements of vitamin B12 levels can be misleading and difficult to interpret, especially if 
the results fall within the lower range of normal or if there is a coexisting deficiency of folic 
acid. 61 Patients with vitamin B12 deficiency should receive therapy with parenteral vitamin 
B12. Even though studies have suggested that oral vitamin B12 may be as effective as 
parenteral vitamin B12, no such studies have been performed in patients with vitamin B12 
deficiency secondary to CD. 62 
2.2.3 Anemia of chronic disease 
In a study focusing on the clinical features of anemia in celiac disease, Harper et al. noted 
that although serum ferritin levels were indicative of iron deficiency in the majority of 
anemic subjects, unexpectedly, in 13% of patients ferritin levels were increased. Because a 
gluten-free diet resulted in increased serum ferritin in iron-deficient patients, but decreased 
ferritin levels in those with previously high ferritins, they concluded that nutritional 
deficiencies alone do not explain anemia in all cases, and that inflammation appears to 
contribute in some individuals, as evidenced by the presence of anemia of chronic disease 
(ACD). In a recent study, Bergamaschi et al. decided to focus on the role of anemia of 
chronic disease in the development of anemia among patients with celiac disease. A peculiar 
feature in the design of this study was the use of refined precision instruments to identify 
anemia of inflammation. At the outset, and in a follow-up period of one year on a gluten-
free diet, they collected data on serum iron, transferrin, serum ferritin, soluble transferrin 
receptor (sTfRc), endogenous erythropoietin (Epo) and IFN-γ. Among 65 anemic celiac 
patients, 45 had uncomplicated iron deficiency anemia, and 2 had cobalamin or folate 
deficiency. In 11 subjects, anemia of chronic disease alone or in combination with iron 
deficiency was identified, a prevalence of 17%. To increase the sensitivity and specificity of 
these blood tests, Bergamaschi et al. employed not only primary data but a combination of 
findings: (a) the sTfRc/log (ferritin) ratio that increases in iron deficiency and decreases in 
ACD, (b) the ferritin/transferrin ratio that decreases in iron deficiency and increases in 
ACD, and (c) the log(Epo) O/P ratio that describes the increase in endogenous serum EPO 
in proportion to the severity of anemia, a response known to be normal in iron deficiency 
anemia but blunted in the anemia of chronic disease.  Compared with a group of 30 non-
anemic celiac subjects, 45 of the celiac patients had findings typical of iron deficiency 
anemia. However, in 11 the findings indicated anemia of chronic disease with decreased 
sTfRc/log(ferritin), increased ferritin/transferrin ratio, and a decreased log(Epo) O/P ratio 
implying a blunted EPO response. Remarkably, serum IFN-γ levels in ACD were 12-fold 
higher than controls, but even in the iron deficient group they were increased 3-fold, 
indicating that some degree of inflammation might have been present in all anemic celiac 
patients. Hepcidin is an important indicator of ACD. By contrast, correlation of iron status 
with hepcidin is limited. The use of a pro-hepcidin assay instead of direct hepcidin 
measurements could explain the failure to demonstrate significant differences in prohepcidin 
levels among the three groups in the above study. In the Bergamaschi et al. study the response 
to a gluten free diet after one year was favorable in both, the IDA and ACD subjects, indicating 
that the suppression of intestinal inflammation by a gluten-free diet can improve anemia both 
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by correcting iron and vitamin malabsorption as well as by abolishing the mechanisms 
responsible for anemia attributable to inflammation.  15, 19, 20, 22 
3. Leukopenia  
Fisgin et al. reported leukopenia and anemia in a few children with celiac disease as the first 
sign of disease. 63 Deficiencies of both folate and copper have been implicated as the 
possible etiology of leukopenia. The data on treatment of these patients are extremely 
limited but initiating a GFD and dietary supplementation with oral copper sulfate if there is 
evidence of copper deficiency, can improve the white blood count. 64, 65, 66 
4. Thrombocytopenia and thrombocytosis 
Thrombocytopenia has rarely been reported in patients with CD and it may have an 
autoimmune etiology.  It has been reported in case reports in association with with 
keratoconjunctivitis and choroidopathy, suggesting an autoimmune pathophysiology. 67 
Therapy for thrombocytopenia in association with CD is unclear, but GFD may result in 
normalization of the platelet count in some cases. 67-69 Thrombocytosis in association with 
CD appears to be more common than thrombocytopenia, occurring in up to 60% ofpatients. 
70-72 The etiology of thrombocytosis associated with celiac disease is unknown, but it may 
be secondary to elevations in inflammatory mediators, autoimmune processes or, in some 
cases, secondary to iron-deficiency anemia or functional hyposplenism. 71, 72 Dupond et al. 
reported that in 14 of 23 patients with celiac disease thrombocytosis was present and it was 
unrelated to iron deficiency or an inflammatory syndrome. Among patients with 
thrombocytosis, 6 had an associated autoimmune disease, but this association was absent in 
patients without thrombocytosis. 73 
Thrombocytosis might probably be useful in the assessment of patients with celiac disease 
and reflect enhanced disease activity. Moreover, the presence of thrombocytes in these 
patients' blood may indicate an associated autoimmune disease. Thrombocytosis may 
resolve after institution of a GFD. 71, 74 Caroccio et al., described an elderly woman 
hospitalized for extreme thrombocytosis associated with severe anaemia who was 
diagnosed with celiac disease. 72 They suggested, that celiac disease should be considered in 
addition to myeloproliferative disorders or other neoplastic conditions in an elderly patient 
when extreme thrombocytosis and severe anaemia is detected. 
5. Venous and arterial thromboembolism 
Ramagopalan et al. postulated in their study that men with celiac disease have a higher risk 
of thromboembolism. 82 Ludvigsson et al. in their study found a significant association 
between celiac disease and venous thromboembolism and they reported that venous 
thromboembolism may be the first clinical sign of celiac disease 83 Though celiac disease is 
not classically thought to predispose to thrombosis, there are several pathophysiological 
mechanisms that have been noted in celiac disease that may contribute to the development 
of a potentially prothrombotic state. 83 Cassela et al. in their study showed that 
hyperhomocysteinemia is relatively frequent in patients with CD, being present in about 
20% of the patients in their series. 84 Hyperhomocysteinemia might represent a link 
between undiagnosed celiac disease and thromboembolism. Hyperhomocysteinemia may be 
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due to genetic factors, with cystathionine beta synthetasis deficiency being considered the 
most common genetic cause, or from acquired folate and vitamine B12 deficiencies (83, 84). 
Homozygous deficiency of N5-N10-methyl tetrahydrofolate reductase, the vitamin B12 
dependent enzyme required for remethylation of homocysteine to methionine, may cause 
hyperhomocysteinemia, and this condition is more problematic to manage compared to 
cystathionine beta synthetasis deficiency, as there is currently no effective therapy 81. 
Moreover, treatment with a gluten-free diet and folic acid in patients with celiac disease and  
N5-N10-methyl tetrahydrofolate reductase variants does not consistently improve 
hyperhomocysteinemia. Thus, celiac disease might lead to increased cardiovascular events 
due to secondary hyperhomocysteinemia, further aggravated by the possible presence of 
genetic abnormalities responsible for hyperhomocysteinemia. 81, 84 Hypofibrinolysis has 
been proposed as another possible cause of thrombosis in patients with celiac disease. 
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a major inhibitor of fibrinolysis. 
Increased plasma TAFI levels are associated with a risk for venous thromboembolism. TAFI 
plasma levels are increased in patients with celiac disease and might contribute to the risk of 
thromboembolism in these patients. 75, 76, 78, 80 Decreased levels of the K vitamin–
dependent anticoagulant proteins, protein S and C, have recently been suggested as a 
causative factor of thrombosis associated with celiac disease too. 77 Antiphospholipid 
syndrome is characterized by arterial and venous thrombosis, and its association with celiac 
disease has been described in a few cases. 85  The clinical spectrum of thromboembolism 
observed in patients with celiac disease is variable, but most cases appear to involve the 
venous circulation and resulting in deep vein thrombosis, pulmonary embolism, Budd-
Chiari syndrome or splenic thrombosis. 79, 80, 81 Only a few case reports have described 
patients with arterial thrombosis, and in those cases the role of CD in predisposing to 
thrombosis is uncertain. 86, 87, 88 Moutawakil et al. Reported a case of a young male lacking 
typical gastrointestinal symptoms who presented with neurologic signs suggestive of an 
ischemic stroke. The mechanisms of vascular damage involving the CNS in celiac disease 
are controversial. The most widely incriminated factor is autoimmune vasculitis due to 
autoantibodies targeting tissue transglutaminase. Other mechanisms for e.g. vitamin 
deficiency are still debated,. 89 
6. Coagulopathy 
Untreated celiac disease may induce malabsorption of many nutrients, which may also 
induce vitamin K deficiency. CD can be associated with abnormalities in coagulation factors 
resulting in a bleeding diathesis. A decrease in K vitamin–dependent coagulation factors 
results in prolongation of coagulation assays or parameters such as the prothrombin time 
(PT), international normalized ratio (INR), and the activated partial thromboplastin time 
(aPTT). 90, 91 Cavalloro et al. found that the prevalence of prolonged PT is about 20% in a 
large series of untreated adult celiac patients, but a prolonged prothrombin time was only 
found in a few patients with subclinical celiac disease (0.9%). Symptomatic patients were 
also more likely to present with a prolonged PT. 92 Patients with CD occasionally present 
with a hemorrhagic disorder as their first symptom. The resulting hemorrhage can be 
minimal to severe. 95 Granel et al. described an interesting case of bilateral adrenal 
haemorrage in a patient with an hypocoagulable state due to untreated celiac disease. 93 
Therapy is initially with parenteral vitamin K, but occasionally plasma products may be 
needed in actively bleeding patients. Malabsorption of vitamin K is uncommon in CD 
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patients who do not have evidence of malabsorption of other nutrients. The treatment 
primarily consists of initiating a GFD and correcting the vitamin K deficiency. 90, 92, 94 
7. IgA deficiency    
Selective IgA deficiency, as defined by the total or severe deficiency of the IgA class of 
immunoglobulins in serum and secretions, is the most common immunodeficiency disorder. 
Studies suggest that 1 in every 500 people may have selective IgA deficiency. Even though a 
large number of individuals with selective IgA deficiency are relatively healthy, there are 
many affected with variety of disorders. These include recurrent sinopulmonary and 
gastronintestinal infections, allergies, and autoimmune disorders. 97, 99 The prevalence of 
IgA deficiency in patients with CD is 10 to 15 times higher than that in the general 
population. Approximately 2% to 3% of CD patients have IgA deficiency, and up to 8% of 
IgA-deficient individuals may have CD. 96, 97, 98 Patients with selective immunoglobulin 
(Ig) A deficiency have a 10- to 20-fold increased risk of celiac disease 99. Cataldo et al. 
reported that the clinical presentation of CD patients with selective IgA deficiency is 
different from that of patients with CD who have normal IgA levels, demonstrating a 
greater incidence of the silent form in the former.  Because of the mild form of clinical 
presentation in IgA-deficient patients with CD, there may be a delay in recognizing such 
cases before appropriate GFD therapy can be instituted.96 The serum antibody markers that 
are currently used in the diagnosis of celiac disease are anti-AGA, ARA, EMA, and tTG 
antibodies. These serologic markers are highly sensitive and specific markers for CD, 
especially for IgA-based antibody tests. Because of the high prevalence of IgA deficiency in 
patients with CD, attention has been focused on the problem of diagnosing such individuals 
and the optimal testing strategy. IgA deficiency can lead to false-negative serology, as most 
of the existing serologic methods detect only IgA antibodies. The basic serologic test that can 
detect IgG antibodies related to CD is the AGA test. However, as the AGA IgG antibody test 
has limited specificity (76-80%), this test alone may not reliably establish a definitive 
diagnosis 99. Evaluating EMA IgG antibodies and anti-transglutaminase antibodies can be 
helpful for diagnosis of celiac disease with IgA deficiency. 99, 100, 101 Celiac disease 
patients with IgA-deficiency are prone to other enteric conditions such as inflammatory 
bowel disease or chronic parasitic infections, especially giardiasis, which could mimic CD. 
Secondly, patients with IgA deficiency are also at risk of developing anaphylactic 
transfusion reactions that may be life threatening if the recipient has anti-IgA antibodies. 96, 
97, 99 
8. Lymphoma 
The association of CD and intestinal lymphoma is well known. 102 This association was first 
described in 1937 by Fairley and Mackie.116 Initially it was thought that the enteropathy 
and malabsorption that occurred was secondary to the lymphoma itself, a concept that 
persisted for many decades until it became apparent that CD often preceded the 
development of lymphoma. Later reports suggested that lymphomas involving the GI tract 
were relatively more common in CD patients and were a major cause of death. 100-105 
Multiple studies now support the association of CD and lymphomas. 106-118 
Patients with celiac disease have a 50- to a 100-fold increased risk of developing lymphoma 
compared with the general population Catassi et al. in their study found that celiac disease 
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was diagnosed in 6 (0.92%) of 653 patients with lymphoma. The odds ratio (adjusted for age 
and sex) for non-Hodgkin lymphoma of any primary site associated with celiac disease was 
3.1 for gut lymphoma, and 19.2 for T-cell lymphoma, respectively. The risk for non-Hodgkin 
lymphoma in this study was 0.63%. 102 The risk of developing an NHL as a complication of 
CD is not fully known, but recent epidemiologic studies suggest a relative risk ranging from 
2.1 to 6.6.112, 113, 116, 117, 132, 133 The risk of contracting lymphoma in the setting of DH 
appears to be increased to a similar degree. 133, 134 Other studies have indicated that there 
may be a much higher risk, ranging from a 15-fold up to 100-fold increase. A recently 
published 30-year population-based study from Finland followed 1147 patients diagnosed 
with celiac disease or DH at a single medical center over 17 245 person-years. This study 
reported an standarized incidence ratio of 3.2 and 6.0 for developing NHL in patients 
diagnosed with CD or DH, respectively. This study provided further support to the theory 
that compliance with a GFD protects against the development of lymphoma in patients with 
CD. 131 Smedby et al. reported that celiac disease is associated with a doubled risk of NHL 
overall  that was mainly attributed to a nearly 20-fold increased risk for T-cell lymphoma 
and to a nearly 3-fold increased risk for diffuse large B-cell lymphoma. There was 
a substantial and statistically significant, increased risk of gastrointestinal NHL and there 
was weak evidence for an increased risk for nongastrointestinal lymphoma. 116 A large 
population-based case-control study undertaken in both Denmark and Sweden assessed the 
risk of NHL in patients with a variety of autoimmune disorders, including CD. Participants 
including 3055 patients with NHL identified through a national hospital and tumor 
registries and 3187 matched controls were surveyed regarding a history of autoimmune 
disorders. Nineteen patients with NHL and 9 controls reported a previous diagnosis of CD. 
CD was associated with a doubled risk of NHL with an OR of 2.1. The odds ratio (OR) for 
diffuse large B-cell lymphoma (DLBCL) was 2.8 in contrast to an OR of 17 for T-cell 
lymphoma. Ten lymphomas were extranodal, including 5 involving the GI tract. The OR for 
gastrointestinal NHL was estimated to be 12 in comparison with an OR of 1.7 for non-
gastrointestinal NHL.116 Many studies suggest that there may be a reduction of risk with 
long-term adherence to a GFD.106,107,110,111,113, 115 A GFD may also reduce the risk in 
patients with DH.135, 136 The benefit of a GFD may be slow in accruing in those who are 
diagnosed later in life.  
In a study by Holmes et al. a two-fold relative risk (RR) of cancer was found, including an 
increased risk of cancer of the mouth and pharynx, oesophagus, and of non-Hodgkin 
lymphoma. 110 The risk was increased, however, in those taking a gluten containing diet 
and when celiac disease was diagnosed late in adulthood. A significant decreasing trend in 
the excess morbidity rate over increasing use of a gluten freed diet and early diagnosis was 
found. The findings of Holmes et al. are suggestive of a protective role for a GFD against 
malignancy in coeliac disease and give further support for advising all patients to adhere to 
a strict GFD for life. 110 
8.1 Enteropathy-associated T-cell lymphoma 
The association between CD and a specific type of intestinal T-cell non-Hodgkin lymphoma 
(NHL), called enteropathy-associated T-cell lymphoma (EATL), appears to be particularly 
strong, but overall these aggressive lymphomas are rare. EATLs are rare lymphomas 
accounting for less than 1% of all NHL.153 EATL appears to be more frequent in Europe, 
where it represents 9.4% of all peripheral T cell lymphomas. An sssociation between EATL 
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and celiac disease is consistently demonstrated in only 30% of patients. The global incidence 
of this lymphoma is rare, being about 0.5 to 1 per million 119. EATL frequently presents as 
multifocal lymphoma with ulcerative lesions and commonly results in bowel perforation or 
other abdominal emergencies. 119, 120, 121 The neoplastic cells of EATL are thought to 
derive from clonal proliferations of phenotypically abnormal intraepithelial lymphocytes 
(IELs). 122, 123 In gluten-sensitive individuals with EATL, 68% are homozygotes for the 
DQB1*02 allele.   Constant over-stimulation of intraepithelial T-cells eventually results in 
neoplastic growth. 129 Loss of CD8 expression by IELs is characteristic for early EATL also 
refereed to as refractory celiac disease type II. Cellier et al. reported that an 
immunophenotypically aberrant clonal intraepithelial T-cell population, similar to that 
observed in most cases of enteropathy-associated T-cell lymphoma, can be found in up to 
75% of patients with refractory coeliac sprue. They suggested that refractory sprue 
associated with an aberrant clonal IEL population may be the missing link between celiac 
disease and EATL. 127 The IELs seen in refractory CD type II have been shown to express 
cytosolic CD3 (cCD3) and are monoclonal on analysis for T-cell receptor gene-
rearrangements. 126, 127 Interleukin-15 is considered an important signaling molecule in 
driving the expansion of IELs. 128 The apperance of phenotypically aberrant monoclonal 
IELs seems to be the first step in the pathogenesis of ETL.123 The etiology of this increase in 
monoclonal IELs remains unknown, but it may be secondary to chromosomal gains or 
mutations of tumor-suppressor genes.  EATL cells typically express CD3, CD7, and CD103, 
they may also express CD30, but are usually negative for CD4, CD5, and CD8. Sometimes 
the EATL cells lack CD3 expression. 123, 126 Immunostaining for CD3, CD8, and CD4 may 
be helpful for initial screening, but molecular-clonality analysis is required for confirmation 
in the cases suspected to have early, evolving or cryptic EATL. 
EATL originates most often in the jejunum. A single or multiple sites within the jejunum 
may be involved with lymphoma. The large intestine and stomach are affected much less 
frequently. EATL rarely causes swollen peripheral lymph nodes that patients can feel. 
Patients will complain of abdominal pain, diarrhea, vomiting and gastronintestinal 
hemorrhage. Weight loss is also commonly reported. This is due to decreased absorption of 
nutrients, especially protein, in the small intestine. Fatigue may also be present due to 
anemia. As many as 40% of patients will present with acute abdominal symptoms, including 
lymphoma-mediated intestinal obstruction or perforation. This is a potentially life-
threatening complication of EATL, requiring immediate surgery. Late in the course of EATL, 
the disease may spread to the liver, spleen and other organs. 136, 137, 138 Diagnosis of 
EATL can be complicated, as many more common disorders can cause abdominal 
symptoms. Most patients will be diagnosed while undergoing exploratory abdominal 
surgery, with a biopsy of the affected lymph nodes. Once the diagnosis of EATL is 
established, patients should undergo diagnostic tests to determine the extent of disease. This 
should include gastrofibroscopy, colonoscopy and enteroscopy, CT scans of the chest, 
abdomen and pelvis, a complete blood count, serum chemistries (including liver function 
tests, lactate dehydrogenase (LDH) and serum albumin) and a HIV test. Hepatitis B testing 
is also recommended due to reports of hepatitis reactivation during chemotherapy.  A bone 
marrow biopsy is optional, as less than 10% of patients with EATL have involvement of this 
organ, but this may be an underestimate due to failure to recognize minimal disease. It  is 
clear from recent studies, that the neoplastic cells are widespread even in the early stage of 
disease pathogenesis. 127 Finally, a baseline echocardiogram to evaluate heart function 
should be done prior to chemotherapy, as some drugs can damage the heart. The essentials 
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for diagnosis of EATL include histopathology and immunochemical staining analysis. 
Therefore mentioned tests enhance the diagnostic yield and establish the stage of EATL for 
each patient. 136, 137, 139  Staging of EATL is as follows 139, 141:  
 Stage I: One involved lymph node group  
 Stage II: Two or more involved lymph node groups on the same side of the diaphragm  
 Stage III: Multiple lymph node groups involved on both sides of the diaphragm  
 Stage IV: Disseminated involvement of other extra-nodal sites, such as the liver or spleen 
Therapy for CD-associated lymphoma is not different from the therapy used in similar 
lymphomas in patients without CD. However, the presence of CD may raise issues of 
malnutrition, an increased risk of infection due to concomitant hyposplenism, and increased 
likelihood of diarrhea or other consequences of CD 143. Combination chemotherapy is most 
frequently used, and the choice of regimen depends on the lineage of the lymphoma. B-cell 
lymphomas are usually treated with combinations such as CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisone) with rituximab. T-cell–derived lymphomas have been 
more challenging to treat.  Therapy of ETL currently remains unsatisfactory, with a 5-year 
survival ranging from 11% to 20% in 2 studies and a 2-year survival of 28% according to 
another study. 142, 143, 144 Survival of patients with T-cell intestinal lymphoma appears to be 
inferior to the survival of patients with intestinal B-cell lymphoma and patients with other types 
of peripheral T-cell lymphomas.140, 141, 142 A recent study reported stem cell transplantation 
in patients with EATL. Results suggested, that patients with novel therapy with IVE/MTX 
(ifosfamide, etoposide, epirubicin/methotrexate) and autologous stem cell transplantation had 
longer survival like patients with standard therapy withou stem cell transplantation. 145 
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